Cabozantinib plus nivolumab granted FDA approval for first-line treatment of advanced kidney cancer
The Food and Drug Administration (FDA) in the United States has approved the cabozantinib (Cabometyx) plus nivolumab (Opdivo) combination for first-line treatment of advanced renal cell carcinoma (RCC) based on the results of the Checkmate 9ER trial. Around 20-30% of people are diagnosed with advanced RCC, and 30% of people treated for early stage RCC go on […]